Abstract
Chronological age is a major risk factor for numerous diseases. However, chronological age does not capture the complex biological aging process. Biological aging can occur at a different pace in individuals of the same chronological age. Therefore, the difference between the chronological age and biologically driven aging could be more informative in reflecting health status. Metabolite levels are thought to reflect the integrated effects of both genetic and environmental factors on the rate of aging, and may thus provide a stronger signature for biological age than those previously developed using methylation and proteomics. Here, we set out to develop a metabolomic age prediction model by applying ridge regression and bootstrapping with 826 metabolites (of which 678 endogenous and 148 xenobiotics) measured by an untargeted high-performance liquid chromatography mass spectrometry platform (Metabolon) in 11,977 individuals (50.2% men) from the INTERVAL study (Cambridge, UK). Participants of the INTERVAL study are relatively healthy blood donors aged 18-75 years. After internal validation using bootstrapping, the models demonstrated high performance with an adjusted R2 of 0.82 using the endogenous metabolites only and an adjusted R2 of 0.83 when using the full set of 826 metabolites with age as outcome. The latter model performance could be indicative of xenobiotics predicting frailty. In summary, we developed robust models for predicting metabolomic age in a large relatively healthy population with a wide age range.
Competing Interest Statement
P.S. is an associate director of applied and statistical genetics at GSK plc. A.S.B. reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and SanofiR.L.-G. is a part-time clinical research consultant for Metabolon, Inc. All other co- authors have no conflicts of interest to declare.
Funding Statement
The INTERVAL study was funded by: NHSBT and the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024) UK Medical Research Council (G0800270) British Heart Foundation (SP/09/002) NIHR Cambridge Biomedical Research Centre Research and Development Programme of NHSBT NHSBT Howard Ostin Trust Fund NIHR Oxford Biomedical Research Centre grant NIHR-RP-PG-0310-1004 The NEO study is supported by the participating Departments the Division, and the Board of Directors of the Leiden University Medical Centre and by the Leiden University Research Profile Area Vascular and Regenerative Medicine. The analyses of metabolites are funded by the VENI grant (ZonMW-VENI Grant 916.14.023) of D.O.M.-K., D.v.H. and R.N. were supported by a grant of the VELUX Stiftung [grant number 1156]. T.O.F. was supported by the King Abdullah Scholarship Program and King Faisal Specialist Hospital & Research Center [No. 1012879283].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The INTERVAL study was approved by The National Research Ethics Service (11/EE/0538). All participants provided written informed consent.
The Netherlands Epidemiology of Obesity (NEO) study was approved by the medical ethical committee of the Leiden University Medical Centre (LUMC) and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Minor formatting and spelling corrections
Data Availability
Data is only available upon request.
